Novartis forms alliance to develop diarrheal disease drug

Novartis has formed a new partnership to support the development of its drug candidate KDU731 to treat cryptosporidiosis, a parasitic disease characterised by diarrhoea. KDU731 is being developed as an inhibitor of the cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase). The drug candidate demonstrated favourable efficacy for treating cryptosporidium infection in preclinical studies and is currently being evaluated in safety studies before advancing into clinical trials. Diarrhoeal diseases are reported to be the cause of around 525,000 childhood deaths each year,